• Home
  • Sustainable Investment Week
    • ESG
    • Sustainable Investment
    • Sustainable Investing
  • Equities
    • UK
    • Global
    • Europe
    • US
    • Asia
    • Emerging markets
    • Specialist
  • Bonds
  • Multi-asset
  • Funds
    • Unit trusts/OEICs
    • Investment Trusts
    • VCTs/EIS
    • Platforms
    • ETFs
    • Pensions
  • Regulation
  • Diversity
  • People moves
  • Events
  • Financial library
  • Industry blogs
  • Digital Edition
  • Newsletters
  • Sign in
    • logged-in-corporate-menuYou are currently accessing Investment Week via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0) 1858 438800

      Email: [email protected]

      • Sign in
     
      • Account details
      • Newsletters
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
    • Newsletters
    • Facebook
    • YouTube
    • Instagram
  • Register
  • Events
    • Upcoming events
      event logo
      European equities: How to stay in sync with the cycle and prepare for recovery

      Our expert panellists on Investment Week’s latest webinar will discuss how investors in Europe should best position themselves for the new economic cycle, which is likely to have very different characteristics from the last.

      • Date: 04 Mar 2021
      • ONLINE, ONLINE
      event logo
      Fund Selector Briefing: Channel Islands 2021

      This interactive briefing will bring together senior investment professionals involved in the fund selection process from across the Channel Islands to hear from and question leading fund managers covering a range of asset classes.

      • Date: 04 Mar 2021
      • ONLINE, ONLINE
      event logo
      Funds to Watch Conference - March

      The Funds to Watch series from Investment Week allows sponsors to show-case up and coming or evolving funds and managers to some of the most influential fund selectors in the UK.

      • Date: 09 Mar 2021
      • ONLINE, ONLINE
      event logo
      Professional Adviser Awards 2021

      Professional Adviser is once more issuing the call for adviser businesses from across the UK to showcase their knowledge, skills and commitment to client care by entering our 2021 Awards.

      • Date: 11 Mar 2021
      • ONLINE, ONLINE
      View all events
      Follow our events

      Sign up to receive email alerts about our events

      Sign up

  • White papers
    • Fidelity logo whitebackground1200 630px 1 120x194
      The ETF Evolution

      In this exclusive magazine exploring the evolution of quality and income ETF strategies, King reveals that each ETF follows an investment strategy developed by the group's in-house research team that leverages fundamental active insights to inform the factor definitions and applies portfolio construction principles to mitigate the unintended biases.

      Download
      7ded04ac5957a69da8d1df41c8f21a0c33988d8f 1 120x194
      A bet on the UK bounce back

      David Cumming, Aviva Investors' chief investment officer for equities, last year witnessed turbulent times for UK equities but he remains positive about the market in which he has a personal as well as a professional stake.

      Download
      Find white papers
      Search by title or subject area
      View all white papers
  • Industry blogs
  • Digital Edition
Investment Week
Investment Week
Sponsored by BMO
  • Home
  • Sustainable Investment Week
  • Equities
  • Bonds
  • Multi-asset
  • Funds
  • Regulation
  • Diversity
  • People moves
  • logged-in-corporate-menuYou are currently accessing Investment Week via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0) 1858 438800

    Email: [email protected]

    • Sign in
 
    • Account details
    • Newsletters
    • Contact support
    • Sign out
 
  • Trending
  • IW 22 Feb issue
  • Past IW issues
  • Jupiter record AUM
  • IA's diversity pledge
  • ESG Festival tickets
  • Technology

Biotech in the fight against cancer

  • BB Biotech
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Share on Whatsapp
  • Send to  
0 Comments

INDUSTRY VOICE: Big players in the healthcare sector are desperate to differentiate their approved 'checkpoint inhibitors' (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new drugs.

Biotechnology firms are developing many of these next-generation combination agents as well as continuing to strengthen their positions in treatments for more niche medical problems.

This makes for an interesting area for investors. Except that the eyes of the investment world point to the ongoing highly charged political debate over drug prices and drug reimbursement programmes. They see the costs of such programmes as a very real threat to biotech companies' creativity, profitability and viability.

If you look at biotech companies which are active in oncology, they have more leeway in setting prices as long as the products they bring to the market deliver superior medical benefits. Currently the unmet medical need in many cancer indications remains very high.

So companies whose drugs cure most quickly and effectively will be more competitive in the marketplace and therefore have more flexibility in setting their prices.

Oncology biotech developments

Celgene

Within our portfolio, BB Biotech's third largest holding is Celgene. There is plenty of attention on the clinical data from Celgene and its partner Bluebird Bio for cell therapy in patients with multiple myeloma. We hope that this process will be classified as ‘breakthrough therapy designation' by the US Food and Drug Administration (FDA). If so this will expedite the development and review of the new drug. Celgene/Bluebird Bio reported improved outcomes, significantly better than the advances achieved with Darzalex, the latest compound to be granted breakthrough therapy designation by the FDA. Final results of the Celgene trial are expected in 2019 with the therapy coming to market as soon as the end of 2019. In the world of drug approvals this seems swift, but precedent was set by the recent speedy approval process of Kite/Gilead's Yescarta treatment of large B-cell lymphoma.

Elsewhere Celgene is due to present clinical trial data on Abraxane as a secondary treatment for pancreatic cancer.

Tesaro

Some of the smaller stocks in our portfolio reported interesting data and it's worth keeping a close eye on them: Tesaro, an oncology focused pharmaceutical experimented with a combination trial in 2017 with Zejula to treat ovarian cancer. By adding on a drug used for the treatment of ovarian cancer, the hope is that Zejula's potential sales could increase substantially beyond ovarian cancer and combat other types of cancer. Tesaro is also due to present further clinical trial data on Niraparib to combat breast cancer.

Incyte

The prospects for Incyte's cancer drug Epacadostat were severely dampened after the latest trial failure with most investors having given up on this drug class. That said the disappointment is now priced in after the recent markdown. Incyte is continuing to work on a range of immuno-oncology treatments.  Impending clinical results from a study of its Jakafi drug (for treating bone marrow disease Myelofibrosis) as a treatment for patients with graft-versus-host disease should be the next market-moving news.

Looking ahead

Immunotherapy combinations are the latest weapon in the battle against cancer. Work on next generation combination agents will continue in the months and years to come. Biotech companies researching cancer treatments currently account for 30% of BB Biotech's entire portfolio. For investors, the future is as exciting as it is hopeful for patients.

Disclaimer

Bellevue Advisors LLP is an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority. This advertisement is directed at professional clients and eligible counterparties as defined by the FCA in the UK only. Past performance is not indicative of future results.

Learn more about BB Biotech

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Share on Whatsapp
  • Send to  
  • Topics
  • Technology
  • Biotechnology
  • BB Biotech
  • Industry Voice
blog comments powered by Disqus
Back to Top
Trustpilot

 

  • Contact us
  • Marketing solutions
  • About Incisive Media
  • Terms and conditions
  • Policies
  • Careers
  • Twitter
  • LinkedIn
  • Newsletters
  • Facebook
  • YouTube
  • Instagram

© Incisive Business Media (IP) Limited, Published by Incisive Business Media Limited, New London House, 172 Drury Lane, London WC2B 5QR, registered in England and Wales with company registration numbers 09177174 & 09178013

Digital publisher of the year
Digital publisher of the year 2010, 2013, 2016 & 2017
Loading